Share This

PR Newswire Asia's news > Biotechnology

 |   Detail   |   Print    Next page > 
     
Everest Medicines Announces Commercial Launch and First Prescription for NEFECON® in Mainland China
2024-05-14T    Biotechnology   Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
Celebration of GV's Second Anniversary Listing-GV Anticipates a New Journey
2024-05-14T    Banking/Financial Service   Biotechnology   Computer/Electronics   Education 
HealthTech Bioactives Partners with Abolis for Sustainable Production of High-Value Polyphenols
2024-05-14T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
HUB Organoids B.V. Awarded Frost & Sullivan's 2024 Technology Innovation Leadership Award for Transforming Drug Development with Highly Advanced Organoid Technology
2024-05-14T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
Allozymes Raises $15 Million in Series A Funding, Poised to Revolutionize Industries with Enzymatic Solutions
2024-05-14T    Biotechnology   Computer/Electronics   Health Care/Hospital 
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
2024-05-14T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer
2024-05-13T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
SK chemicals Targets the North American market with Circular Recycling Technology participating in NPE 2024
2024-05-13T    Banking/Financial Service   Biotechnology   Green Technology 
BGI-HL OHA Lab inaugurated in Harbin, initiating colorectal cancer risk assessment for 800,000
2024-05-13T    Banking/Financial Service   Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
SCG Cell Therapy Presented New Preclinical Data in an Oral Presentation at ASGCT 2024 Annual Meeting Highlighting Superior Tumor Inhibition of its Immunoswitch Armored HPV-TCR T Cell Therapy (SCG142) against a Broad Range of HPV-associated Cancers
2024-05-13T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
  Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.